The research in this proposal will examine the regulation of (Na+,K+)-ATPase in vivo by norepinephrine and by a specific endogenous inhibitor of the enzyme. (Na+,K+)-ATPase is the enzymatic basis of energy-dependent Na+ and K+ transport and has a central role in the regulation of intracellular cation concentrations and, hence, of membrane potential, cell excitability, and energy utilization. The experiments in this proposal are in four parts. 1) Experiments examining regulation of (Na+,K+)-ATPase, and interactions between norepinephrine and thyroid or adrenocortical hormones in regulation of (Na+,K+)-ATPase, and interactions between noradrenergic regulation of (Na+,K+)-ATPase and other mechanisms of Na+ Ca++ transport. 2) Experiments on specificity of transmitter regulation of (Na+,K+)-ATPase will examine specificity with respect to a) transmitter, receptor subtype, and tissue, b) molecular form of enzyme, using polyacrylamide gel electrophoresis to separate the two forms of enzyme, and c) localization of enzyme regulated by norepinephrine, using radioautography. The latter experiments will provide pilot data for development of studies using positron emission tomography. 3) Experiments on the mechanism of the noradrenergic effects will examine (Na+,K+)-ATPase-mediated transport in vitro. Initial experiments will compare effects in synaptosomes, dissociated brain cells, and brain slices. Further experiments will examine transmitter specificity, effects of prior exposure to norepinephrine, hormone status, or treatment with psychoactive drugs in vivo, effects of electrical stimulation in vitro, and roles of cation fluxes and of cyclic nucleotides. 4) Experiments in man will use stimulation of cation shifts by endogenous catecholamines to develop a means for examining noradrenergic regulation of (Na+,K+)-ATPase in intact man. These studies will provide the basis for studies of noradrenergic regulation of (Na+,K+)-ATPase in normal man and in conditions related to functions of the norepinephrine-(Na+,K+)-ATPase system, including affective disorders, eating disorders, and disorders of neural arousal.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH037141-06
Application #
3376067
Study Section
(PCBB)
Project Start
1985-09-01
Project End
1989-08-31
Budget Start
1987-09-01
Budget End
1989-08-31
Support Year
6
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Steketee, J D; Silverman, P B; Swann, A C (1989) Forebrain norepinephrine involvement in selective attention and neophobia. Physiol Behav 46:577-83
Swann, A C; Steketee, J D (1989) Subacute noradrenergic agonist infusions in vivo increase Na+, K+-ATPase and ouabain binding in rat cerebral cortex. J Neurochem 52:1598-604
Swann, A C; Steketee, J (1989) Forskolin infusion in vivo increases ouabain binding in brain. Brain Res 476:351-3
Swann, A C (1989) Noradrenaline and thyroid function regulate (Na+,K+)-adenosine triphosphatase independently in vivo. Eur J Pharmacol 169:275-83
Swann, A C (1988) Thyroid hormone and norepinephrine: effects on alpha-2, beta, and reuptake sites in cerebral cortex and heart. J Neural Transm 71:195-205
Swann, A C (1988) Norepinephrine and (Na+, K+)-ATPase: evidence for stabilization by lithium or imipramine. Neuropharmacology 27:261-7
Swann, A C (1988) Dexamethasone and adrenalectomy alter brain (Na+,K+)-ATPase responses to noradrenergic stimulation or depletion. Eur J Pharmacol 158:43-52
Swann, A C; Gottesfeld, Z (1987) Deafferentation elicits a transient decrease in Na+, K+-ATPase activity and ouabain binding in the olfactory tubercle. Brain Res 404:323-6
Swann, A C (1986) Brain Na+,K+-ATPase: alteration of ligand affinities and conformation by chronic ethanol and noradrenergic stimulation in vivo. J Neurochem 47:707-14
Swann, A C (1985) (Na+,K+)-ATPase and noradrenergic regulation: effects of cardiac glycoside treatment and noradrenergic manipulations. Eur J Pharmacol 119:67-74

Showing the most recent 10 out of 12 publications